UTHR

United Therapeutics Corporation

315.13 USD
+6.15 (+1.99%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

United Therapeutics Corporation stock is up 14% since 30 days ago. The next earnings date is Jul 31, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 56% of the previous 25 June’s closed higher than May. In the last 10 Unusual Options Trades, there were 9 CALLs, 1 PUT. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
17 Jun 13:30 16 Aug, 2024 290.00 CALL 25 32
17 Jun 13:53 19 Jul, 2024 280.00 CALL 49 328
18 Jun 13:39 19 Jul, 2024 280.00 CALL 50 279
18 Jun 16:05 21 Jun, 2024 280.00 CALL 20 1176
18 Jun 17:52 21 Jun, 2024 240.00 CALL 4 97
18 Jun 17:52 21 Jun, 2024 240.00 CALL 4 97
18 Jun 17:52 21 Jun, 2024 240.00 CALL 5 97
18 Jun 19:04 16 Aug, 2024 290.00 PUT 36 117
18 Jun 19:56 16 Aug, 2024 320.00 CALL 48 25
20 Jun 16:08 20 Dec, 2024 320.00 CALL 288 2

About United Therapeutics Corporation

United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise. Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD)